Halozyme Therapeutics (HALO) Goodwill (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Goodwill data on file, last reported at $582.3 million in Q1 2026.

• On a quarterly basis, Goodwill rose 39.71% year-over-year to $582.3 million in Q1 2026; TTM through Mar 2026 was $582.3 million, a 39.71% increase from a year earlier, with the FY2025 full-year figure at $580.4 million, up 39.23% from the prior year.
• Goodwill for Q1 2026 stood at $582.3 million, roughly flat from $580.4 million in the prior quarter.
• Over the last five years, Goodwill for HALO reached as high as $582.3 million in Q1 2026 and fell as low as $199.5 million in Q2 2022.
• Historically, Goodwill has averaged $409.7 million across 5 years, with a median of $416.8 million in 2023.
• Across the five-year window, Goodwill surged 108.95% in 2023 and changed 0.0% in 2024, its largest moves.
• Year by year, Goodwill stood at $409.0 million in 2022, then gained by 1.9% to $416.8 million in 2023, then changed by 0.0% to $416.8 million in 2024, then jumped by 39.23% to $580.4 million in 2025, then rose by 0.34% to $582.3 million in 2026.
• Per Business Quant data, the three most recent Goodwill figures were $582.3 million in Q1 2026, $580.4 million in Q4 2025, and $416.8 million in Q3 2025.